Source: Eur Respir J, 50 (5) 1701670; 10.1183/13993003.01670-2017
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
Jose A. Caminero, Alberto Piubello, Anna Scardigli, Giovanni Battista Migliori. Bedaquiline: how better to use it. Eur Respir J, 50 (5) 1701670; 10.1183/13993003.01670-2017

Member's Comments

No comment yet.

Related content which might interest you: Bedaquiline in MDR/XDR-TB cases: first experience on compassionate use Source: Eur Respir J 2014; 43: 289-292 Year: 2004 Rational use of anti-tuberculosis drugs in the EU: better patient care and less drug resistance Source: Eur Respir J 2012; 39: 802-804 Year: 2012 Antituberculosis fixed multi-dose combination and single drug therapy in active tuberculosis: What is the benefit? Source: Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions Year: 2011 Investigating the steroids and long-acting β2-agonists combination: why do we need more? Source: Eur Respir J 2004; 23: 501-502 Year: 2004 The goal is to go further and do better: but how? Source: Eur Respir Rev 2015; 25: 1-3 Year: 2016 Time to ban short-acting ß-agonists and use anti-inflammatory treatment as required to improve outcomes Source: Virtual Congress 2021 – Wheezing illnesses along the life span Year: 2021 Fixed-dose combination antituberculosis therapy: is the INH dose adapted for the Tunisianpopulation? Source: International Congress 2018 – Challenges in tuberculosis care Year: 2018 Does combination therapy lead to better adherence in asthma? Source: Annual Congress 2010 - Combination therapy in asthma and COPD Year: 2010 Long-term oral antibiotic treatment: why, what, when and to whom? Source: Eur Respir Monogr 2017; 75: 185-205 Year: 2017 Do technologies make a difference in adherence to treatment: instant messaging application use? Source: Virtual Congress 2020 – Digital health interventions in respiratory medicine Year: 2020 SABINA: global programme to evaluate prescriptions and clinical outcomes related to short-acting ß2-agonist use in asthma Source: Eur Respir J, 55 (2) 1901858; 10.1183/13993003.01858-2019 Year: 2020 New short regimens for latent tuberculosis treatment: safety first! Source: Eur Respir J, 52 (6) 1802180; 10.1183/13993003.02180-2018 Year: 2018 Four-month regimens: are they feasible? Source: International Congress 2015 – Tuberculosis: short-course chemotherapy Year: 2015 Aiming for total control in asthma: an ineffective use of resources? Source: Eur Respir J 2005; 26: Suppl. 49, 429s Year: 2005 TB following targeted and biological therapy: can we predict it? Source: Virtual Congress 2020 – Tuberculosis and comorbidities Year: 2020 Introducing a new formulation of pirfenidone to reduce tablet burden for the IPF patient: Is it tolerable? Is it easy to take? What do our patients think? Source: International Congress 2018 – Management of idiopathic interstitial pneumonias: established and new treatments Year: 2018 Tuberculosis elimination, patients' lives and rational use of new drugs: revisited Source: Eur Respir J 2016; 47: 664-667 Year: 2016 Biodiesel: is it any safer to use? Source: International Congress 2018 – Occupational and environmental lung diseases: mechanisms, biomarkers and causation Year: 2018 Budesonide/formoterol provides better efficacy at a lower or similar cost as compared to high-dose salmeterol/fluticasone treatment Source: Annual Congress 2007 - Cost-effectiveness in diagnosis, therapy and care Year: 2007 The MABA approach: a new option to improve bronchodilator therapy Source: Eur Respir J 2013; 42: 885-887 Year: 2013